Most patients who ask about SPRAVATO® already know it works differently than a standard antidepressant prescription. What tends to be less clear, until someone explains it directly, is what actually happens at a certified treatment center: what the first appointment involves, what a session looks like, and what to plan for practically. This post is a plain-language walkthrough of the full SPRAVATO® process at Catalyst Psychiatry in Corvallis.
Your First Appointment at Catalyst Psychiatry in Corvallis Is a Consultation
SPRAVATO® is not a medication you receive on the day you first ask about it. The first step at Catalyst Psychiatry is a consultation appointment, and its purpose is assessment and planning, not treatment.
During that consultation, we gather relevant medical information, conduct our own clinical evaluation, and determine whether SPRAVATO® may be appropriate for you. We also verify your insurance coverage as part of that process. If SPRAVATO® is recommended, we build a treatment plan with you and enroll you in the SPRAVATO® REMS Program before any sessions are scheduled.
The REMS Program, which stands for Risk Evaluation and Mitigation Strategy, is a safety program required by the U.S. Food and Drug Administration for SPRAVATO® (U.S. Food and Drug Administration). It exists because SPRAVATO® can cause temporary effects, including sedation and dissociation (a feeling of detachment from your thoughts, feelings, or surroundings), that require clinical monitoring during and after each dose. Enrollment in the REMS Program means that both you and our clinical team agree to a set of protocols that govern how treatment is delivered.
If, after your consultation, SPRAVATO® does not appear to be the right fit, we discuss what other treatment approaches may be relevant to your history and goals. Results vary by individual, and the consultation is where that picture starts to come into focus.
Why SPRAVATO® Must Be Administered in a Certified Setting
Understanding why SPRAVATO® must be administered in a certified clinic rather than at home helps make the entire process easier to prepare for.
SPRAVATO® targets NMDA receptors, which are part of the glutamate system, the brain’s primary excitatory neurotransmitter network. NMDA receptors play a central role in synaptic plasticity, meaning the brain’s capacity to form and reorganize neural connections (National Institutes of Health). Acting on these receptors is what makes SPRAVATO® clinically distinct from serotonin- or norepinephrine-targeted antidepressants, and it is also what produces temporary perceptual and mood effects during the time the medication is active. Those effects require clinical oversight to be managed safely, which is why certified treatment centers like Catalyst Psychiatry are the only setting in which this treatment is available.
This is not a bureaucratic requirement. It is a clinical one, and it is built into how the medication was designed to be used.
What a SPRAVATO® Session Involves and What to Expect
Each session takes place at our Corvallis office. Before administration, we check your blood pressure. SPRAVATO® can cause a temporary increase in blood pressure that may last for approximately four hours after a dose, so blood pressure monitoring before and for at least two hours after each session is required. If your blood pressure reading is elevated above a safe threshold before a session, we will not proceed that day.
SPRAVATO® is self-administered as a nasal spray. You use the device yourself under the direct observation of our clinical team. After administration, you remain at the clinic for the mandatory monitoring period. During that time, you can sit quietly, read, or listen to something. You should not plan to work, and you cannot drive.
What to Expect During the Monitoring Window
The monitoring period lasts at least two hours after each SPRAVATO® dose. What you experience during that window varies from patient to patient and can change across sessions. Not everyone experiences all of the possible temporary effects, and their intensity varies.
The most commonly reported effects include dissociation, dizziness, nausea, sedation, and a sense of numbness or of feeling detached. Some patients describe feeling mildly anxious, dizzy, or briefly euphoric. These effects are temporary and, in most cases, resolve before the observation period ends. Dissociation is the effect patients most often ask about in advance — having a clinical team present during this window is precisely why the supervised model exists, and most patients tell us that knowing what to expect in advance makes the experience significantly more manageable than they anticipated.
If you experience chest pain, shortness of breath, a sudden severe headache, changes in vision, or a seizure after a SPRAVATO® dose, tell our team immediately.
Driving, Transportation, and Other Logistics
You cannot drive on the day of a SPRAVATO® session. This restriction applies not just during the observation window but for the remainder of that day. You will need to arrange transportation to and from our office for every session. This is a firm clinical requirement.
Our office hours run Monday through Thursday from 8:30 a.m. to 4:30 p.m., and Friday from 8:30 a.m. to noon. Sessions are scheduled during those hours. For patients managing work schedules or caregiving responsibilities, planning each session days in advance is something we encourage from the start. If scheduling is a concern, raise it when you call; our front desk team can work through options with you.
Insurance Coverage and Cost
SPRAVATO® is covered by most insurance plans, and we verify your specific coverage during your consultation appointment before recommending any treatment. We are in-network with Providence, Pacific Source, First Choice Health, TriCare, Moda, Compsych, Samaritan Choice, Optum, UHC Commercial, United Behavioral Health, Triwest, and Regence Blue Cross Blue Shield. At this time, we are not accepting Medicare, Medicare Advantage plans, or Oregon Health Plan for SPRAVATO® treatment. For patients with questions about out-of-pocket costs, the SPRAVATO® With Me patient support program, offered through Johnson & Johnson, includes financial assistance resources for eligible patients (Johnson & Johnson).
Frequently Asked Questions About SPRAVATO® Treatment
Do I take SPRAVATO® at home or at the clinic?
At the clinic. SPRAVATO® is self-administered as a nasal spray, meaning you use the device yourself, but only at a certified treatment center under the direct observation of a clinical team. You remain at the clinic for at least two hours after each dose for monitoring. Taking SPRAVATO® outside of a certified setting is not permitted under the FDA’s REMS Program requirements.
How long should I plan for each SPRAVATO® session?
Plan for approximately two to two and a half hours per session, from arrival through the end of the observation window. Some sessions may run longer depending on how your blood pressure stabilizes. We recommend not scheduling other commitments immediately after a session, particularly during the first several weeks of treatment when you are still learning how you respond individually.
What side effects are common during SPRAVATO® treatment?
The most commonly reported temporary effects include dissociation, dizziness, nausea, sedation, and a brief increase in blood pressure. Less common effects include vomiting, feeling anxious, or a spinning sensation. Results vary by individual, and not everyone experiences all of these. Our clinical team is present throughout the monitoring period to observe and respond.
Can I drive myself home after a session?
No. Driving on the day of a SPRAVATO® session is not permitted. You will need to arrange transportation to and from our office for every treatment session. This applies regardless of how well you tolerate the medication or how mild your experience during the monitoring window was.
What if I decide partway through treatment that I want to stop?
That decision is always yours to make. If you choose not to continue SPRAVATO® treatment, we ask that you communicate with our team so we can understand your experience and discuss whether any adjustments or alternatives may be relevant. There is no obligation to complete a fixed number of sessions, and no treatment proceeds without your ongoing informed participation.
Key Takeaways
- Your first appointment at Catalyst Psychiatry is a consultation: we assess eligibility, verify insurance, and enroll you in the SPRAVATO® REMS Program before any sessions are scheduled.
- SPRAVATO® is self-administered as a nasal spray at our Corvallis office under direct clinical supervision, with a mandatory monitoring period of at least two hours after each dose.
- Temporary effects during the monitoring window can include dissociation, dizziness, nausea, and sedation; these typically resolve before the observation period ends, and results vary by individual.
- Driving is not permitted on the day of a SPRAVATO® session; transportation must be arranged in advance for every appointment.
- SPRAVATO® is covered by most major insurance plans; we verify your coverage during the consultation appointment before recommending any treatment.
Understanding what SPRAVATO® treatment actually involves, in practical terms, is what makes it possible to decide whether to pursue a conversation with a provider. At Catalyst Psychiatry, that conversation begins with a consultation at our Corvallis office, where we review your history, determine whether you may be a candidate, and walk through every step of what treatment would look like. Call us at 541-730-4400 or reach out through our website to schedule. The decision about whether to pursue treatment belongs to you, and our job is to give you the information to make it clearly.
References
National Institutes of Health. NMDA receptors and synaptic plasticity: mechanisms and clinical relevance. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965111/
Johnson & Johnson. SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. https://www.jnj.com/…
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. SPRAVATO® treatment should only be pursued under the supervision of a licensed psychiatric provider who is familiar with your full medical and psychiatric history. Individual results vary, and not all patients respond to SPRAVATO®. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.